Compared side by side
BPC-157 vs ARA-290: how they differ
The short answer
BPC-157 is a peptide derived from a protective protein in human gastric juice that, in animal studies, speeds the repair of tendons, ligaments, muscle and gut lining. ARA-290 is 11 amino acids copied from erythropoietin (EPO) that reach its tissue-repair receptor without raising red cells, and its four small randomized phase 2 trials measured nerve symptoms. BPC-157 is taken once or twice daily, commonly for 4–12 weeks; ARA-290’s trials gave it daily for 28 days or 12 weeks.
Side by side
| Compared | BPC-157 | ARA-290 |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Body Protection Compound 157, BPC157 | Cibinetide, ARA290, pHBSP, Helix B surface peptide, HBSP |
| What it is | A peptide derived from a protective protein in your stomach. | Eleven amino acids copied from the water-facing side of one helix in erythropoietin, the hormone that drives red-cell production — residues that sit side by side on that face, strung into a new chain rather than a stretch cut out of the hormone. |
| How it works | Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining. | An 11-amino-acid peptide copied from the water-facing side of helix B in erythropoietin (EPO). It binds the innate repair receptor — the EPO receptor paired with CD131, the beta common receptor — rather than the EPO receptor pair that drives red-cell production, so in lab and animal work it carries EPO's tissue-protective, anti-inflammatory signal without raising red cells. In rats with an injured nerve it reduced allodynia for weeks and damped the spinal microglia response. In people, four small randomized phase 2 trials measured nerve-symptom scores and corneal nerve-fiber density. |
| Commonly reported | Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots. | Burning and tingling settling over the first one to two weeks, often with nothing to feel for a while first; one user who ran it for a pinched nerve noticed no change. Four small randomized trials exist and no approval. |
| Studied range | Research range: 200–500 mcg. Studied in research — not a recommendation. | Research range: 1–4 mg, starting dose 1 mg. Studied in research — not a recommendation. |
| How often | Once or twice daily | Daily |
| Half-life | ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes) | ~20 minutes (measured in healthy volunteers after a SubQ dose; about 2 minutes after IV, and its developers argue a brief exposure is enough because the receptor acts as a switch) |
| Route | SubQ injection, IM injection, Oral (less studied) | SubQ injection |
| Typical run | Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely. | The published daily courses ran 28 days (three trials) and 12 weeks (the eye study). Community runs commonly last about four weeks and are repeated later. In the trial that followed people longest, the symptom improvement was still measurable 12 weeks after the last dose, and nine months after; nothing beyond 12 weeks of daily dosing has been studied. |
| Evidence | Emerging: primarily preclinical / limited human data | Moderate: animal studies + some human data |
| Common side effects | Nausea (rare), injection site irritation, vivid dreams, dizziness | Injection site reaction, headache, light-headedness, fatigue, nausea |
- Category
- BPC-157Healing & recovery
- ARA-290Healing & recovery
- Also known as
- BPC-157Body Protection Compound 157, BPC157
- ARA-290Cibinetide, ARA290, pHBSP, Helix B surface peptide, HBSP
- What it is
- BPC-157A peptide derived from a protective protein in your stomach.
- ARA-290Eleven amino acids copied from the water-facing side of one helix in erythropoietin, the hormone that drives red-cell production — residues that sit side by side on that face, strung into a new chain rather than a stretch cut out of the hormone.
- How it works
- BPC-157Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
- ARA-290An 11-amino-acid peptide copied from the water-facing side of helix B in erythropoietin (EPO). It binds the innate repair receptor — the EPO receptor paired with CD131, the beta common receptor — rather than the EPO receptor pair that drives red-cell production, so in lab and animal work it carries EPO's tissue-protective, anti-inflammatory signal without raising red cells. In rats with an injured nerve it reduced allodynia for weeks and damped the spinal microglia response. In people, four small randomized phase 2 trials measured nerve-symptom scores and corneal nerve-fiber density.
- Commonly reported
- BPC-157Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
- ARA-290Burning and tingling settling over the first one to two weeks, often with nothing to feel for a while first; one user who ran it for a pinched nerve noticed no change. Four small randomized trials exist and no approval.
- Studied range
- BPC-157Research range: 200–500 mcg. Studied in research — not a recommendation.
- ARA-290Research range: 1–4 mg, starting dose 1 mg. Studied in research — not a recommendation.
- How often
- BPC-157Once or twice daily
- ARA-290Daily
- Half-life
- BPC-157~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
- ARA-290~20 minutes (measured in healthy volunteers after a SubQ dose; about 2 minutes after IV, and its developers argue a brief exposure is enough because the receptor acts as a switch)
- Route
- BPC-157SubQ injection, IM injection, Oral (less studied)
- ARA-290SubQ injection
- Typical run
- BPC-157Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.
- ARA-290The published daily courses ran 28 days (three trials) and 12 weeks (the eye study). Community runs commonly last about four weeks and are repeated later. In the trial that followed people longest, the symptom improvement was still measurable 12 weeks after the last dose, and nine months after; nothing beyond 12 weeks of daily dosing has been studied.
- Evidence
- BPC-157Emerging: primarily preclinical / limited human data
- ARA-290Moderate: animal studies + some human data
- Common side effects
- BPC-157Nausea (rare), injection site irritation, vivid dreams, dizziness
- ARA-290Injection site reaction, headache, light-headedness, fatigue, nausea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
BPC-157
- Day 1–7 Week one: early hints, for some
- Day 7–14 Pain often starts to ease
- Day 14–21 Pain often eases by week three
- Day 21–28 Many report a calmer gut
- Day 28–42 The slower part of repair
- Day 42–56 Six weeks in: taking stock
- Day 84+ Past week 12, the data runs thin
ARA-290
- Day 1–14 The first two weeks: for some, the burning eases
- Day 14–28 Four weeks is where the trials looked
- Day 28–56 What happened after the dosing stopped
- Day 56–120 Past the trials' window
Together or one or the other
BPC-157 and ARA-290 are a common stack: ARA-290 lists BPC-157 among its common stacks.
Community · ARA-290
Different jobs: the nerve and the tissue
A pairing the community reaches for when an injury hurts in a nerve way as well as a structural way. The split is honest: ARA-290's human data is about nerve symptoms and nerve-fiber counts, while BPC-157 and TB-500 rest on animal work about blood supply and repair cells moving in. Nothing has tested them together.
Questions people ask
How long do BPC-157 and ARA-290 last?
The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes). The half-life of ARA-290 is ~20 minutes (measured in healthy volunteers after a SubQ dose; about 2 minutes after IV, and its developers argue a brief exposure is enough because the receptor acts as a switch).
How often are BPC-157 and ARA-290 taken?
BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied). ARA-290: daily. Route: SubQ injection.
How are BPC-157 and ARA-290 dosed in research?
The research range for BPC-157 is 200–500 mcg. The research range for ARA-290 is 1–4 mg, with a 1 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of BPC-157 and ARA-290?
For BPC-157, the library lists: nausea (rare), injection site irritation, vivid dreams, dizziness. For ARA-290: injection site reaction, headache, light-headedness, fatigue, nausea.
Are BPC-157 and ARA-290 taken together?
BPC-157 and ARA-290 are a common stack: ARA-290 lists BPC-157 among its common stacks. A pairing the community reaches for when an injury hurts in a nerve way as well as a structural way. The split is honest: ARA-290's human data is about nerve symptoms and nerve-fiber counts, while BPC-157 and TB-500 rest on animal work about blood supply and repair cells moving in. Nothing has tested them together.